Epidemiologic evidence increasingly treats muscle-strengthening activity as an independent risk factor, not an adjunct to aerobic exercise. A systematic review and meta-analysis of cohort studies found muscle-strengthening activities associated with lower risk of cardiovascular disease, total cancer, diabetes, and all-cause mortality — with a notable dose–response pattern in which benefit appeared at low weekly volumes.
Separate analyses have examined resistance exercise specifically against cardiovascular morbidity and mortality, and against mortality risk generally, with directionally consistent results.
Low muscle mass is itself a prognostic marker across the continuum of care, associated with longer hospital stays, higher complication rates, and reduced treatment tolerance. Intervention studies in specific disease populations — including a meta-analysis in prostate cancer patients — report improvements in strength and functional outcomes during treatment.
Hemodynamic data from patients with chronic congestive heart failure has also helped clarify that controlled resistance exercise produces manageable cardiovascular responses, informing prescription in populations that were historically excluded from strength training.